InMed Pharmaceuticals Inc (INM)

[SVX95]

NetworkNewsWire Announces Publication of Discussion on the R&D of Cannabinoids for Medical Use

Marketwired MarketwiredMarch 16, 2017
NEW YORK, NY--(Marketwired - Mar 16, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals ( CSE : IN ) ( OTCQB : IMLFF ), an NNW client that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems.

The publication, entitled, "Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth," discusses the rampant growth of the cannabis market and how a number of biotech companies are developing cannabinoid-based therapies to address unmet medical needs.

To view the full publication visit: https://www.networknewswire.com/biotech-innovations-drive-cannabinoid-based-pharmaceutical-market-growth/

"Topical delivery, targeting to treat diseases on a local (rather than systemic) basis, is a preferred approach for various cannabinoid therapies, especially those targeting skin conditions. Canada-based InMed Pharmaceuticals, Inc.'s (IMLFF) flagship product, INM-750, is a cannabinoid-based topical therapy for a rare skin condition called Epidermolysis Bullosa (EB). As of now, there is no cure for EB. INM-750 is the first treatment ever developed specifically for this disease that has the potential to accelerate wound healing and skin regeneration; alleviate several symptoms such as inflammation, itching and pain; and possibly reverse the course of the disease through the modulating of keratins in the skin. With a potential global market of $1 billion per year, the treatment is being developed for topical application so as to maximize efficacy while minimizing side effects."

InMed's pipeline is further discussed in the publication, alongside a look at several industry peers.